# Excision BioTherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/excision-biotherapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.excision.bio
- Total disclosed funding: $71M
- Latest round: Series A (Feb 3, 2021)
- Investors on record: 11

## About

Excision BioTherapeutics Inc. specializes in the development of CRISPR-based therapies aimed at treating viral infectious diseases, particularly HIV, herpes simplex viruses, and hepatitis B.Founded in 2015, Excision BioTherapeutics Inc. is headquartered in San Francisco, US. The company focuses on innovative gene-editing solutions for chronic viral infections. CEO Daniel Dornbusch leads the organization, which has secured a total of USD 60.74 mn through various funding rounds, with the latest being a GRANT of USD 6.85 mn from the California Institute for Regenerative Medicine. The firm has successfully completed 8 deals to advance its therapeutic initiatives.Excision BioTherapeutics, Inc. specializes in developing CRISPR-based therapies that target viral infectious diseases, specifically focusing on human immunodeficiency virus (HIV), herpes simplex viruses (HSV 1&2), and hepatitis B. The company's core product offerings include EBT-101, EBT-104, and EBT-107, designed to leverage proprietary gene-editing technology to potentially cure these chronic infections and improve the quality of life for affected patients. These therapies are currently in various stages of clinical development, with findings and data presented at significant scientific meetings, such as the ASGCT Annual Meeting. Excision's products aim to serve both healthcare providers and patients suffering from viral diseases, primarily within the North American and European markets, where there is a significant burden of chronic viral infections.Excision BioTherapeutics generates revenue through collaborations and partnerships with leading research institutions and pharmaceutical companies. These strategic alliances facilitate the advancement of its therapeutic products through clinical trials and ultimately to market. The company’s revenue model includes funding from research grants, strategic partnerships, and potential licensing agreements related to its CRISPR technology. While specific pricing plans for its therapies have not been disclosed, revenue is expected to be derived from B2B transactions involving partnerships with healthcare organizations and possibly direct-to-consumer avenues as products gain market approval. Given the innovative nature of the therapies, the company anticipates generating substantial interest from healthcare providers and researchers seeking solutions for viral diseases.Excision BioTherapeutics plans to expand its product pipeline by advancing EBT-101, EBT-104, and EBT-107 through clinical trials. The company is targeting expansion into European markets by 2025, leveraging recent funding, including a GRANT of USD 6.85 mn from the California Institute for Regenerative Medicine, to support these initiatives. Additionally, Excision BioTherapeutics has raised undisclosed venture funding from SGInnovate, which will further bolster its research and development efforts.

## Funding rounds

- Series A, Feb 3, 2021, $61M — Norwest Venture Partners, ARTIS Ventures, GreatPoint Ventures, Celesta Capital, Cota Capital, Anzu Partners, Gaingels, Celesta Capital, Adjuvant Capital, Loreda Holding, Olive Tree Capital
- Seed, Mar 1, 2020 — Bioverge
- Seed, Sep 6, 2017, $10M — ARTIS Ventures

## Investors

- ARTIS Ventures (https://capitalatlas.ai/funds/artis-ventures) — Seed, Series A
- Bioverge (https://capitalatlas.ai/funds/bioverge) — Seed
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series A
- GreatPoint Ventures (https://capitalatlas.ai/funds/greatpoint-ventures) — Series A
- Celesta Capital (https://capitalatlas.ai/funds/celesta-capital) — Series A
- Cota Capital (https://capitalatlas.ai/funds/cota-capital) — Series A
- Anzu Partners (https://capitalatlas.ai/funds/anzu-partners) — Series A
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series A
- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series A
- Loreda Holding — Series A
- Olive Tree Capital (https://capitalatlas.ai/funds/olive-tree-capital) — Series A